Navigating Compliance Changes: New Guidance from the HCCA Compliance Institute Written By ProviderTrust Share this Okay. Good afternoon, everyone, or morning, depending on where you’re located. Thanks so much for joining today, and welcome to our informational session on the twenty twenty three HCCA Compliance Institute. We will be covering today some important topics related to managed care and the new guidance that was unveiled by the office of inspector general. Today, myself and my colleague, Reagan, who’s on the line, will be the panelists of our discussion with ProviderTrust chief compliance officer, Donna Theel. As a reminder, you have been muted on the line upon entry to to the webinar. I think we posted this in the chat. But if you have questions along the way, feel free to drop those in the chat, and we’ll get to them at the end. So, Donna, let’s go on and begin with a quick summary of what you heard at this year’s compliance institute. Thanks, Allison and Reagan. Welcome, everybody. Welcome to another hopefully valuable webinar today. We’re happy to have all of you. As always, the HCCA Institute always provides, some good information for us, those of us in the compliance world and and hopefully for those, that are interested in compliance. We really, saw a variety of topics. Certainly, quality and access to to, to care was a a very important thing. Spent a lot of time really looking at, what post COVID looks like. Right? Now that we’re ending the PHE, there were a lot of sessions, on that topic. Certainly, the inspector general shared a lot of great information, surrounding really how high the stakes are in, health care companies today and for the payers and and really truly to our patients. So, we’ve learned a lot of great nuggets, from the inspector general. I wanna take just a couple of minutes, and go through some areas that we’re not gonna focus on, but that, that we’re not gonna kinda do a deep dive in, but that I thought were really important, for those of you that didn’t have an opportunity to, participate at the compliance institute this year. One of the areas, that they released, and spoke about, at the institute was a new telehealth, toolkit that the OIG put together. And, I think all of us can agree that whenever the OIG provides their toolkits, it’s really, a guidebook for all of us in the compliance world to, to take a peek at what what good looks like. They really focused on not just the provider side, but also the payer side. Right? Really looking at how, we should be monitoring just fraud, waste, and abuse from a telehealth perspective. Right? It talked about how to analyze the claim volumes, the type of information, the type of services that are being provided, the volumes of services being provided. So just a a really good compliance tool, for those of you, that are utilizing or paying for telehealth services. So something to look at if you, have not seen that toolkit yet. Another area and and one, that’s probably near and dear to my heart, my background prior to coming to ProviderTrust was in the post acute world. And, the office inspector general, really made it very clear that their two primary areas of focus this year are, managed care and nursing homes. So I grew up in that space. And so one of the things that they talked about was a three part framework that they’re calling it, and they call it PRO, the PRO, framework. PRO stands for performance, residents first, and oversight. And I think, as the inspector general kinda talked about this pro, this new framework, she really spoke to how compliance fits into all three of those. So I would strongly encourage you again to kinda take a peek, if you’re in the post acute space and specifically in the nursing home, skilled nursing area to look at those three areas. So performance really is really understanding incentives and and what, in their mind, is driving, per poor nursing home performance, and what we should do, to really to monitor those incentives to make sure that they’re incentivizing high quality of care, right, to improve the overarching, care that’s being provided to the residents in the nursing facilities. The next one was what their and, again, those of you in this space are familiar with the term worthless service, but really trying to to look at and and continue to enforce, false claims as it relates to, worthless service. So, again, how can we as compliance professionals monitor and look at, quality of care initiatives, within the nursing facility. And then the o is is oversight. Right? Really making sure that, we’re self identifying issues and and correcting those things as quickly as possible and how compliance fits into that. The other area that I just wanted to highlight kind of fits right into, this nursing home perspective, and that’s the role of private equity. They highlighted the fact that, there’s been more than one trillion dollars, in over eight thousand deals relative to private equity in the last ten years, in the last decade. That number felt really high. You know, we think about a word like a trillion dollars. So they’re really, kinda really questioning what the impact of quality care is based on this influx of private equity and whether or not, the financial motivation is greater than, the quality of care initiative. So, they’re very clear, and I think we’ve seen that in messaging from the OIG, that they’re gonna be looking at private equity and and really delving into the that ownership component and disclosure of ownership. And and we know, from the role that we play here at ProviderTrust and and monitoring that ownership and those owners, is a really important part of a good compliance program. So those were a couple of areas that I just wanted to highlight separate and distinct from kind of this deeper dive conversation that Alice and Reagan and I are gonna have. So, that’s what I think maybe as kind of a a quick overview of some of the highlights at, the Combiniance Institute this year. Thanks, Donna. So jumping into some of the structural changes that were covered at the compliance institute and the growth of managed care. Donna, how how has that managed the growth in managed care, impacted compliance efforts and specifically for payer compliance programs? How are expectations shifting, and how should these programs prepare? Yeah. That’s a great question, Reagan. I think, it’s never ending. It feels like great. The the managed care side, is just continuing to grow and grow and grow. We’re really starting to see, just clear increased numbers of individuals. Right? We know that nearly half of all of the, Medicare beneficiaries are now in a Medicare Advantage Plan. Right? So that makes, a big difference. We also know that there’s value based care that’s coming out of the managed care side of it. And then, some just changes in what we would maybe consider nontraditional payers, right, where states kind of I think the the term that we heard at the institute was payviders. Right? So there are providers and payers that are coming together and creating a whole new world of, of entities that are providing and paying for services. And and that certainly increases, risk for the organization and really trying to understand who who you know, which side are we monitoring and and watching from a compliance perspective. I think it creates complexity, and it certainly adds, just a level of additional level of scrutiny, right, from the OAG. We’re really trying to see what those incentives are, between both arms of the same organization. So that certainly, is important. I think, again, the inspector general, she made it very clear that her their two, areas of focus are managed care and nursing homes. So these changes that are coming, are are drawing a lot scrutiny by the office inspector general, the Department of Justice. And one area that, was interesting to me and I think when I think about what should a compliance program look like or what should we do or how do we move forward, I always like to see some of the cases that the OIG or DOJ talk about. So, one of the examples at the institute was, based on the risk adjustment payment model. And just for a quick background, make sure we’re all on the same page. Right? It’s, it’s really designed to compensate for, you know, really increased treatment of older or sicker beneficiaries. Right? Making sure that there isn’t preferential enrollment. Right? That’s kind of the the concept behind it. They’re paying more to the health plans to care for those patients or those beneficiaries that are, sicker or have more medical needs. And there there really is some challenge with that risk adjustment. And so one of the examples that they shared was that they had looked into twenty insurance companies, that had received over five billion dollars in risk adjusted payments. And the the and this was in two thousand seventeen when they did this study, and they received sorry. These twenty companies received half a billion. Right? This five hundred and five billion, sorry, in risk adjustment patients, specifically for patients who had a diagnosis of a serious mental illness. So a huge amount of money specifically on one diagnosis type that we know receives a higher, reimbursement rate. Then when they went and looked at the records of these particular patients, they never received any treatment for that that mental health issue. So they were kind of drawing that conclusion that we’re paying for these monies based on a claim, right, based on a, a component of the claim that says, hey. This is the risk adjustment component. But then when they dug into the medical record and actually looked for the treatment of that person, they didn’t have the services. Example of the way the, you know, office inspector general, the Department of Justice are really working together, right, to be really highly scrutinizing. So when I think about, like, what should I be doing, I would start right here. Right? I would start in all the guidance that the OIG is is giving us on the additional scrutiny on why they care, the areas that they’re concerned about, and I would, would focus on that. Thanks, Donna. I like that the term, pay byters has been coined. That’s interesting. So you said that the percentage of Medicare and Medicaid enrollees and managed care continues to increase. What steps should the payers take to adapt to that change? I think, again, I I I would be sitting back and and just looking at where are my risks internally? Do I understand my risks? Do I understand these patient populations? What’s changing? Right? I believe the statistic that we saw is that nearly ninety percent of Medicaid beneficiaries are enrolled in some sort of an insurance plan. Right? So some payer. And so when we think about what the Medicare rules are and we say there’s about fifty percent of Medicare beneficiaries that are in a a Medicare Advantage program, and then we have ninety percent of Medicaid patients in a, insurance plan of some sort. Those rules aren’t always the same. And so understanding the regulatory requirements from a Medicaid perspective remember, Medicaid is state, so each state may have a different contract and different sets of rules around eligibility. So making sure we understand that, making sure we understand what the Medicare components are. And then I would be looking at my organization, and I would be saying, do I have subject matter experts across, my organization that understands these rules? I would be asking myself where does compliance live within my organization. Right? Is it centralized? Is it decentralized? Is there clear accountabilities and roles defined for compliance? Have we done a recent risk assessment? Right? We know that in, you know, during, the public health emergency, things are kind of quiet. I don’t wanna say they were quiet. They were very noisy in in some ways. But regulatory, wise, we didn’t have a lot of new regulations coming out. Things were relatively flat from that perspective. And now we’re coming back in, and eligibility is changing for in the Medicaid space quite a bit. So how are we managing that, and and do we know where compliance lives? And when we say that compliance is such an important focus on managing these, risks, I would just make sure I know who and how and and what they’re they’re really working on right now. And that’s that’s where I would start is just a a basic kind of understanding of of who in my organization. I was just looking at my notes, and I don’t wanna leave out a quote that I thought was was really important, from the inspector general. And she said, it can be virtually impossible for health care organizations to succeed in this type of environment without a clear way to navigate through problems that will inevitably incur occur. It requires practice risk assessment and expert compliance methods to ensure that health care providers deliver high quality of care and use financial management as well as reduce organizational risks that may arise from powerful new incentives. Right? And so we think about risk adjust risk adjustment, on the payer side and all these changing rules and and just the importance that our, our compliance professionals play in the managed care world, I think, again, is where I would probably start. Awesome. Thanks, Donna Donna for that guidance. I think it’s it’s really interesting to hear from you everything you heard, especially that quote from the inspector general. So shifting away now from managed care for a moment, we have hinted earlier in the webinar at the unveiling of a new guidance or regulatory change that was announced by the OIG at this year’s HCCACI. Can you share what that guidance is and how it may impact health care organizations moving forward? Absolutely. So what Allison’s referring to is, during one of the, sessions, Laura Ellis, who’s, with the office inspector general, someone I know well from my past life, shared that the next iteration of the corporate integrity agreements will include a new requirement and that relates to monitoring, Medicaid, state Medicaid exclusions. As you all know, the corporate integrity agreement is is kind of a road map of what the office inspector general expects, to be a part of a good, compliance program. And we know that every year or two or three depends, the office inspector general adds new things to the corporate integrity agreement as, again, the road map to us, as providers and payers as to what the kind of the, baseline of compliance needs to be. So by adding, the state Medicaid exclusions into the previous requirement of just, the federal exclusion, right, you had to monitor the OIG and SAM. But I think we’ve all felt best practice was to monitor all the state Medicaid lists. And now the OIG has come, and put that in a corporate integrity agreement and said you monitor all the exclusion state Medicaid exclusions in the state in which you operate. Great. I think you answered this a little bit. But due to that update to the CIA, what, new policies will health care organizations have to put in place? I assume it would have to do with adding the state Medicaid oversight. And how can do would you recommend for teams to operationalize these changes? Yeah. Great question. It it really does take, expands the requirement. Again, we think best practice is to monitor all those states. We also know that that can be really difficult. Right? We know that the state, exclusion lists are very different from each other. They don’t have the same sort of data. They don’t have necessarily the same frequency of publishing that information. They don’t have the same method of publishing that information. Some of them have, like, Texas looks very similar to, the OIG list, but then you have other states that just have an Excel spreadsheet or a PDF. And so, when I look at what what policy or process, it would really be understanding the states in which I operate and making sure that I understand, where I might only operate in the state, but where do I have patients that might be coming in or out, cross borders, right, where someone’s or visiting and I’m in a hospital from a different state. Really just making sure, that I understand which states that I’m specifically accountable for, and then really looking at my my resources. Right? How am I gonna do this? Do I have a, you know, do I have a partner like ProviderTrust who’s already taken care of that for me and I can, I can feel really great that I don’t have to think about that? Or am I doing it manually and now I need to figure out how to capture that data and how to, to complete that that really, that task of looking at multiple states probably. And and then what is the the frequency. Right? We know the OIG list is updated, monthly, and the expectation is at a minimum, right, that you would be looking at that monthly. So applying that same standard, to the frequency would also be a process that you would wanna look at and consider how you’re gonna incorporate that. So, Donna, you you kinda started hinting at, the guidance around excluded in one state. Are you excluded in every state? That can kind of be fuzzy. If your organization is not under CIA and you’re just trying to put, best practices in place for monitoring, What is what is the guidance there around excluded in one state, excluded in all states? I really wish I had a black and white answer for you, Reagan. I could tell you that, sadly, the guidance is, yes, excluded in one, excluded in all. We know the enforcement of that, though, is inconsistent across states. Like, there are some states that absolutely positively, use that that guideline as it it doesn’t matter. If they’re excluded anywhere, they are not allowed to practice in in our state. In other states, that doesn’t seem to be the case. Maybe a kind of a random example, I guess. California, for example, on their exclusion list that you will see exclusions from all over the country. They, have a a practice of of giving seeing exclusions in other states and adding that to to their exclusion list. So best practice certainly is to look across the United States. Right? Making sure that, you are aware of the exclusions cross borders. I think another, reason for that is just we have seen, you know, nefarious actors moving from state to state. Right? If I’m in trouble in this state, I can, you know, go across the border literally to the next state. And, hopefully, the the, you know, bad action hasn’t followed me fast enough, and I can I’m not excluded in that state, or I can potentially get a license in another state, relatively quickly. So so being able to to see kind of the where someone’s been excluded, I think from a, ethical consideration, do you want someone, working in your organization that’s been excluded by another state without at least understanding the story, right, without at least knowing the history of it, why it happened, when it happened, so that you can make a good business decision, as to what’s best, whether it’s whether it’s to pay that provider or to, let that provider practice in your organization. I would always strongly encourage that we look across all the states recognizing that that can be a challenge and, making sure that you clearly understand, especially when you’re looking at state Medicaid, what what is your agreement with the state. Right? What what’s in that agreement that you have, and what does it say that you must do? Does it say you must look across states? Does it say you just need to look in your state? Really making sure you understand. And does it clearly delineate who can practice or or who you can pay, under your Medicaid agreement. Thanks, Donna. And, the last six years of working with providers and payers and trying to, give guidance on best practices for monitoring, that’s been the number one question that we’re consistently asked over and over again, and it just remains it remains unclear. So before we conclude our discussion, I think that this went a little quicker than we thought it would. Let’s consider just some key takeaways from the compliance institute for the payer space and for the provider space. So, Donna, for our payer audience, what should they continue to focus on in regards to, kind of the the guidance that was given specifically or specifically directed toward managed care, and what are what monitoring should they think about putting in place as they’re adopting new strategies? I think I would wanna start that answer with again, you know, to quote the inspector general, I I felt like she just really did a great job of celebrating the compliance professionals in in the audience and and the value proposition that they bring. And and she stated specifically related to, to managed care, compliance professionals can help counterbalance powerful incentives in managed care that raise financial, legal, and quality of care risks. And and I think that’s something that if if I’m, you know, kinda taking to heart, I would break that apart, right, and think about powerful incentives in managed care that raise financial, legal, and quality of care risks. And, I would wonder, like, how does my compliance program really align with those kind of three components? Again, in the managed care world, how how am I involved from a compliance oversight perspective in legal decisions? What does that look and feel like? How are we consulted? Are we consulted early on? Are we consulted after the fact when there’s when there’s already, an issue at hand? Are we part of that conversation in in really understanding a new change like like what we’re just talking about. Right? Adding state Medicaid exclusion monitoring into our process. Where, where does that fit in? How how would I do that in my new world? I would think about the, right, the the financial component. Right? When we’re when the OIG talks about, how payers are incentivized. Right? How are we looking at that? How are we doing that risk evaluation within our organization as we’re making these potential changes in the organization. Right? Do we understand that? Does compliance have a seat at the table? Right? We always talk about, the earlier you can bring compliance into a conversation, hopefully, that you can move faster as opposed to letting compliance come in at the end and then have compliance say, oh, man. That didn’t quite work. We’re gonna have to kinda roll all that back. Right? So I think that would be something really important. And then specific to, the Medicaid component of of monitoring, again, as a payer, I’d be just trying to really get wrap my head around what states are we actually not only are we, have kind of in network. Right? But what are those out of network? Like, are we familiar with with how many practitioners are are referring practitioners or nonpar practitioners, right, that are coming in such that I’ve opened my door to higher liability. And and does it make sense to, to capture that and just do all the states? Do I wanna limit it? Really doing a deep dive and, again, selfishly on the provider trust side, wondering how how we could automate that. Right? What can we do to automate that so it isn’t so burdensome and and really feel confident that we’re identifying potential bad actors as early as possible either, you know, in a pre claims process or as quickly thereafter that we can or in a credentialing process as well, right, as we’re looking at, credentialing new per practitioners into our organization or into our our peer network. Awesome. Thanks, Donna. And shifting over to our provider audience, what would you say is the most critical thing they should consider in relation to not only managing those compliance efforts, but kind of operationalizing, thinking about resource allocation with the announcement of this new guidance? I think, maybe somewhat of what we just talked about, right, is is who who, how, and when. And, depending on the size of your organization, what does that look and feel like? Quality of data is not great on the state Medicaid side. So what am I prepared to do? How am I going to look at that information? How am I gonna resolve some of that information? How do I, do investigations? Do I understand, who to contact in the in the kind of in that state exclusion list? Is there a party that I haven’t considered before that I need to, to look and to think at how and and when. Just assigning accountabilities. Are we clear on who’s doing what within the organization? I think it’s really important as well. If you’re a health system, is it centralized or decentralized? Do I let each of my hospitals or my nursing homes or whatever it might be? Practice location, take on that accountability. Do I need to roll that up into kind of a more, you know, corporate role? I would always be considering all of those risks and size and time, as I’m looking at specifically in in that one area. So there’s two other resources that I just wanna mention before we close out that, came out, this during the institute that are coming later this year or early twenty twenty four. And those are new, compliance program guidance, new CPGs from the OIG. And, again, right, we’re always looking for the best tool and the road map that we can get from our, government friends. And the two that they’re coming out with, first are, of course, managed care and nursing homes. So I would be, watching for those. We the the OIG has consistently, shared, right, that they wanna be collaborative and they want to respond to, to the the needs of prior providers and the payers both, and that they feel the new CPGs are going to be, just easier to read. They’re obviously way better than the federal registers that we read when we’re looking for regulatory information. And they, they kinda highlighted that they’re gonna be modernized. So we’ll be excited to see those, in early, twenty twenty four, I guess. Someone hinted in one of the sessions I was at that they they may actually be out in q four, but I’m sure they’re wishing for us to kind of focus on, being available in twenty twenty four. So we’ll all what did they say? Overprom or over I I can’t remember. Overpromise under the over under whatever that is. Overpromise. Overdeliver. There you go. Thank you. The other thing I just wanted to highlight that I thought was really interesting, and it really, I think, helps us think about when we’re thinking about our compliance programs and and the things that are kind of fundamental to self to self identification. Right? The government wants to give us credit, right, when we self identify an issue and and and fix it or in some cases, self disclose. And when, the inspector general started her comments, one of the things that she highlighted was, that the at the end of twenty twenty two, they had hit quite a quite a milestone, and that was one billion dollars returned to the government through, the health care fraud, self disclosure protocol. Right? And, she really celebrated that with the compliance professionals in the room just saying the hard work that goes on behind closed doors within our organizations to self identify and work with leadership and really help, educate people on on the value of of not only self identification, but when self disclosure has to happen, you know, kind of the the benefits of of doing the self disclosure and how we not only are protecting our our beneficiaries, but we’re ultimately protecting the organization from reducing ongoing risk, right, and financial penalties and, being you know, letting the government identify that fraud versus us coming forward and and just stopping the bleeding, if you will, and and self reporting. So I think those are just two things really, to to help us remember that the work that we’re doing in self identification of our issues, the OIG is is recognizing and and valuing what the role of compliance is today. One of the another quote was meaningful compliance oversight pays dividends, not only for federal health care programs and taxpayers, but for all health care. So I I think that is maybe what I would wanna end on from from my perspective is, we have road maps. We have, validation from, office inspector general of the value and the importance of compliance and compliance professionals. And I hope that, each of us finds a way to to really be, voices at the table early and often in helping navigate the risks within our organization and and helping reduce those risks in a timely fashion, which ultimately leads to, better patient outcomes and and less fraud. So, I appreciate the opportunity. I turn it over to Allison and Reagan for whatever questions. Yeah. I think we’re just gonna move into taking some poll questions. Yes. And everyone, so sorry for the confusion. I think we said put your questions in chat, but chat seems to be disabled. That was our fault. So please put any questions you have in the q and a section. If we don’t get that to them today, we’ll be happy to follow-up with you on our answer. But we did have a couple come through here. One was, asking if the slides will be sent after, and we will be sending the full recording afterwards. So you will have access to those slides to review this as needed. And then, Donna, one came through that I think is pretty thought provoking, so get ready. So I’ll do my best. It asks, how can health care organizations strike a balance between financial success and then ethical practices in the growing managed care industry? That is thought provoking. I think, whoever asked that question, if you find the magic bullet, you can go on a consulting spree and make lots of money. But in all seriousness, it’s really hard. Right? It’s I I shouldn’t say it’s really hard. I think it is it just challenges all layers of the organization to be collaborative and transparent. I think working in silos and building different streams of payment, ideas or, internal incentives. Like, we think about referral bonuses. We think about, like, census development. We just there’s so many different areas that potentially, cause conflict between, you know, the operations team and the marketing team and the sales team and the payer group and the billing group and quality. Right? There’s there’s a healthy tension. And and I would say, making sure that that healthy tension is addressed head on. Right? Making sure that we are sitting in the boardroom, that we are sitting as leaders in the organization, having that that conflict openly and and really truly making sure that you have alliance professionals in your organization that are that are experienced and knowledgeable, that they can come to the table with not a no, but with a how can we do this the right way? And and I really truly believe that our role as a compliance professional is not to say no. Our way is to say our our objective is to help the business grow in a healthy way and protect our patients and ensure the highest level of care in a healthy way. Right? So I think there is balance. I don’t think it’s easy in any way, shape, or form. But I think as long as we are thoughtful in understanding the regulatory guidance, we are kinda leveraging the resources maybe outside of our organization that we need to that if we don’t have the internal expertise to help us, I think we are getting like, the pay by or is a classic example. Right? Our our industry is becoming, bigger and smaller all at the same time. Right? We’re having all of these acquisitions, and and we’re kinda cross pollinating our payers and our providers into one, and that creates instant risk. And so making sure that we’re thoughtful about the legal entity structure. Do you have more than one compliance professional? I’m sure you do. Like, is there compliance over the payer side and over the provider side that have two different levels of experience that are both coming into that conversation. I I don’t have the secret sauce in any way, shape, or form. I don’t have a road map. I don’t have anything I can send you after this call. But, truly, my my my experience is transparency early and often and making sure compliance is at the table and is not the last check mark on a to do list. They’re they’re really at the beginning in the conversation. Thanks, Donna. I think that’s, great advice. Another question that came in, I think this is in regards to the the CIA new guidance. So from a provider standpoint, how will this new guidance impact our relationship with Medicaid programs in the states that we currently do business in? I’m not sure I can I don’t know that it will change? My guess is that in your agreement, it told you you already had to check that list. Whether or not anyone read that, realized that, is doing that might be the question. I think I I think what this guidance or this inclusion into the corporate integrity agreement does is just raises the bar if, for example, if you have someone in your organization that is excluded by the OIG and they’re also excluded at a state level, that the OIG is gonna be expecting you in your self disclosure, to acknowledge that and and talk about, like, what actions you’ve done, what research you’ve already done, what exclusion monitoring you’ve already done, and and look at the Medicaid payback, as well, in whole, not just in in part. So I don’t know that it specifically changes your relationship With the Medicaid agency, I think it just ensures that you’re looking at that that state. And remember, there are not exclusion lists publicly available in every state. I believe we’re at forty five right now, states that have Medicaid exclusion lists. So making sure you know what states are or are not, publishing their lists would be really important too. Yep. Awesome. Okay. And we got a really good I think this is more of a statement than a than a question for you, Donna, directed right at you. So I’ll just read that off. It says, Donna, I just so agree with looking across all markets. The reputational harm from having a bad actor in one of the markets where with little effort you can mitigate that is not a good business practice. Separately, provider contracts can require disclosure of any sanctions or exclusions as a provider participation requirement. Noting payment will be recovered for services which has due process, but for not meeting participation requirements. Wholeheartedly agree. Awesome statement. Great. Okay. I think that’s all the questions we got. Like I said, feel free to keep sending them in, and we’ll be happy to follow-up with any answers. But thank you guys for joining. We will be sending the recording out afterwards. Thank you, Donna, for all your your great advice and explanation of these new guidances. I think this was really great and helpful to everyone. So thanks again. Thanks, everyone. Have a great day. June 22, 2023 Donna Thiel, Chief Compliance Officer at ProviderTrust, shares her expertise and valuable feedback from the 2023 HCCA Compliance Institute. Gain exclusive insights into the evolving healthcare landscape and the latest OIG compliance guidance that was unveiled at the conference. Webinar Takeaways: Gain exclusive insights into the new guidance announced by the Office of Inspector General (OIG). Understand the implications and impact of the new guidance on compliance efforts, operational adjustments, and resource allocation for healthcare organizations. Learn about the steps healthcare organizations should take to effectively adapt to the changing landscape resulting from the increasing percentage of Medicare and Medicaid enrollees in managed care, and the projected shift to Medicare Advantage plans. Discover how to ensure effective monitoring and identification of both OIG and state Medicaid exclusions, and how to integrate the monitoring of state Medicaid exclusions into existing compliance programs.